As illustrated in Figures 4F,H, the MPO activity and MDA levels in the treated groups were lower than those in the IBD group, with the LU + QR group showing reductions of 52.6 and 20.2%, respectively. The gene discussed is BCAM; the disease is inflammatory bowel disease.